```html

Kawasaki‑like Syndrome (Multisystem Inflammatory Syndrome in Children – MIS‑C)

Overview

Multisystem Inflammatory Syndrome in Children (MIS‑C), often described as a Kawasaki‑like syndrome, is a rare but serious condition that occurs in children and adolescents after infection with SARS‑CoV‑2, the virus that causes COVID‑19. It shares many clinical features with classic Kawasaki disease (KD) – such as fever, rash, and coronary artery inflammation – but typically presents with more pronounced multisystem involvement, including the gastrointestinal, respiratory, and neurologic systems.

Who it affects: MIS‑C predominantly affects children 5 – 14 years old, though cases have been reported from infancy to young adulthood (up to 21 years). Slight male predominance (≈ 60 %) has been observed, and the syndrome is more common in children of Black, Hispanic, or South Asian ancestry.<sup>CDC</sup>

Prevalence: As of 2024, the CDC estimates ~ 2 – 5 MIS‑C cases per 100 000 individuals under 21 years in the United States, with peaks following major COVID‑19 waves. Worldwide, > 7 000 cases have been reported across > 60 countries.<sup>WHO</sup>

Symptoms

MIS‑C is defined by a combination of fever, laboratory evidence of inflammation, and involvement of at least two organ systems after recent SARS‑CoV‑2 exposure. The symptoms can evolve rapidly over days.

General / Constitutional

• Fever – ≥ 38.0 °C (100.4 °F) lasting ≥ 3 days (most common, present in > 95 % of cases).
• Fatigue or malaise.
• Headache.

Skin & Mucous Membranes (Kawasaki‑like features)

• Polymorphous rash (often maculopapular, resembling “measles”).
• Cracked, red lips and “strawberry” tongue.
• Conjunctival injection (non‑purulent eye redness).
• Swelling or redness of hands and feet, sometimes with desquamation (peeling) in the subacute phase.

Cardiovascular

• Chest pain or tightness.
• Palpitations.
• Hypotension or shock (often due to myocardial dysfunction or vasodilatory shock).
• Elevated cardiac enzymes (troponin, BNP).
• Coronary artery dilation or aneurysms – the hallmark complication shared with KD.

Gastrointestinal

• Abdominal pain (often severe, mimicking appendicitis).
• Vomiting.
• Diarrhea.

Respiratory

• Shortness of breath.
• Cough.
• Persistent low‑grade hypoxia.

Neurologic

• Confusion or altered mental status.
• Headache.
• Seizures (rare, but reported).

Other

• Kidney injury (elevated creatinine, reduced urine output).
• Liver inflammation (transaminitis).

Causes and Risk Factors

Unlike classic KD, which has an unknown trigger, MIS‑C is strongly linked to a recent SARS‑CoV‑2 infection.

• Post‑infectious immune dysregulation: The prevailing hypothesis is that a delayed, exaggerated immune response to viral antigens leads to widespread inflammation.
• Timing: Symptoms typically develop 2‑6 weeks after a confirmed or suspected COVID‑19 infection, often when the initial viral illness was mild or asymptomatic.
• Genetic susceptibility: Certain HLA types and polymorphisms in immune‑regulatory genes may predispose children to hyper‑inflammation.

Risk Factors

• Age 5‑14 years (peak incidence).
• Male sex.
• Ethnicity: Black, Hispanic, South Asian.
• History of COVID‑19 infection (positive PCR or antigen test, or positive SARS‑CoV‑2 antibodies).
• Underlying immune‑mediated conditions (e.g., asthma, autoimmune disease) – data are limited but suggest a modest increase in risk.

Diagnosis

Diagnosis relies on a combination of clinical criteria, laboratory markers, and imaging. The CDC and WHO provide similar case definitions; clinicians often use the American College of Rheumatology (ACR) MIS‑C criteria.

Step‑by‑step diagnostic approach

1. Clinical assessment: Persistent fever ≥ 3 days plus ≥ 2 organ system involvement.
2. Laboratory evidence of inflammation:
   • Elevated C‑reactive protein (CRP) > 3 mg/dL.
   • Erythrocyte sedimentation rate (ESR) > 40 mm/hr.
   • Elevated ferritin, D‑dimer, fibrinogen, or procalcitonin.
   • Neutrophilia with lymphopenia.
3. SARS‑CoV‑2 testing:
   • Positive PCR or antigen test within the preceding 4 weeks, OR
   • Positive serology (IgG antibodies) indicating past infection.
4. Cardiac evaluation:
   • ECG – may show ST changes or arrhythmias.
   • Echocardiogram – assesses ventricular function and coronary artery dimensions.
   • Cardiac MRI (if echo equivocal) for myocarditis.
5. Imaging of other systems:
   • Abdominal ultrasound or CT if severe pain suggests intra‑abdominal pathology.
   • Chest X‑ray or CT for pulmonary involvement.
6. Rule out alternative diagnoses:
   • Septic shock, toxic shock syndrome, bacterial myocarditis, macrophage activation syndrome, or classic Kawasaki disease.

Key diagnostic criteria (CDC)

Criterion	Requirement
Fever	≥ 38 °C ≥ 24 h (usually ≥ 3 days)
Laboratory evidence of inflammation	Elevated CRP, ESR, or other markers
Multisystem involvement	≥ 2 organ systems
Evidence of SARS‑CoV‑2 infection	Positive test or serology
Exclusion of alternative diagnoses	Clinical judgment

Treatment Options

Early, aggressive therapy improves outcomes and reduces the risk of coronary artery complications. Treatment is usually administered in a hospital, frequently in an intensive care unit (ICU).

First‑line Immunomodulation

• Intravenous immunoglobulin (IVIG): 2 g/kg as a single infusion. Proven to lower fever, decrease inflammatory markers, and reduce coronary artery dilation (adapted from Kawasaki disease protocols).<sup>Cleveland Clinic</sup>
• Aspirin: High‑dose (30‑50 mg/kg/day) until afebrile for 48 h, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect, especially if coronary changes are noted.

Second‑line / Adjunctive Therapies

• Corticosteroids: Methylprednisolone 1‑2 mg/kg/day (or pulse 10‑30 mg/kg) for patients refractory to IVIG or with shock.
• Biologic agents (targeted cytokine blockade):
  • Anakinra (IL‑1 receptor antagonist) – useful for severe inflammation or macrophage activation syndrome.
  • Tocilizumab (IL‑6 receptor blocker) – considered when IL‑6 levels are markedly elevated.
  • Infliximab (TNF‑α inhibitor) – reserved for IVIG‑resistant cases.
• Anticoagulation: Low‑molecular‑weight heparin or aspirin‑plus‑clopidogrel in patients with markedly elevated D‑dimer or documented thrombus.

Supportive Care

• Fluid resuscitation and vasopressors (e.g., norepinephrine) for shock.
• Ventilatory support if respiratory failure develops.
• Renal replacement therapy for acute kidney injury (rare).
• Empiric broad‑spectrum antibiotics until bacterial infection is excluded.

Follow‑up and Long‑Term Management

• Repeat echocardiograms at 1‑2 weeks, 4‑6 weeks, and then at 3‑6 months to monitor coronary arteries.
• Cardiology referral for any persistent ventricular dysfunction or aneurysms.
• Gradual tapering of steroids over 2‑4 weeks under pediatric rheumatology guidance.

Living with Kawasaki‑like Syndrome (MIS‑C)

Even after hospital discharge, many families face anxiety about recurrence and long‑term heart health. Below are practical tips for day‑to‑day life.

Medication Adherence

• Maintain the aspirin regimen as prescribed; low‑dose aspirin is usually continued for 6‑12 weeks if coronary changes were present.
• Use a pill organizer or reminder app to avoid missed doses of steroids or biologics.

Cardiac Monitoring

• Schedule all cardiology appointments; keep a copy of echocardiogram reports.
• Learn to take a child's pulse and recognize signs of tachycardia or irregular rhythm.

Activity & Exercise

• During the acute phase, restrict strenuous activity; once cleared by a cardiologist, gradual return to normal activity is safe.
• Avoid competitive sports for at least 3 months if coronary aneurysms were detected.

Nutrition & Hydration

• Offer a balanced diet rich in fruits, vegetables, whole grains, and lean protein to support immune recovery.
• Encourage adequate fluid intake, especially if on diuretics or after fever.

Emotional Support

• Children may feel isolated after a prolonged hospital stay; involve school counselors and peer support groups.
• Parents should monitor for anxiety or depression and seek mental‑health resources if needed.

Vaccination

• COVID‑19 vaccination is recommended for eligible children (≥ 5 years) after recovery, as it reduces the risk of reinfection and potentially another MIS‑C episode.<sup>CDC</sup>
• Maintain routine immunizations (MMR, DTaP, etc.) per the local schedule.

Prevention

Because MIS‑C follows SARS‑CoV‑2 infection, prevention focuses on reducing COVID‑19 transmission.

• Vaccination: Full primary series + booster for age‑eligible children.
• Masking & ventilation in indoor public settings during community surges.
• Hand hygiene: Frequent handwashing with soap for ≥ 20 seconds.
• Testing & isolation when a child is symptomatic or exposed.
• Prompt treatment of acute COVID‑19 when indicated (e.g., antivirals) may theoretically lower the inflammatory cascade, though data are limited.

Complications

If untreated or delayed, MIS‑C can progress to life‑threatening complications.

• Coronary artery aneurysms – seen in 10‑15 % of untreated cases; may lead to myocardial infarction later in life.
• Cardiogenic shock – due to myocarditis or severe ventricular dysfunction.
• Thromboembolism – especially with high D‑dimer levels.
• Multi‑organ failure – renal, hepatic, or respiratory failure requiring ICU support.
• Neurologic sequelae – seizures, encephalopathy, or peripheral neuropathy.
• Long‑term cardiac dysfunction – up to 4 % of patients have persistent reduced ejection fraction at 6‑month follow‑up.<sup>NIH Journal of Pediatrics</sup>

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS‑C) Overview. Updated 2024.
2. World Health Organization. WHO Rapid Report on MIS‑C. 2023.
3. Cleveland Clinic. MIS‑C Treatment Guidelines. 2024.
4. Mayo Clinic. Multisystem Inflammatory Syndrome in Children (MIS‑C). 2023.
5. Feldstein LR, et al. “Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.” New England Journal of Medicine. 2020;383:334‑346.
6. Whittaker E, et al. “Clinical Features of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS‑CoV‑2.” JAMA. 2020;324:259‑269.
7. Kim AS, et al. “Long‑Term Cardiac Outcomes in Children with MIS‑C.” Pediatrics. 2023;152:e202103658.

```